Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252829 | 0.98 | SIGMAR1 (0.58) | SIGMAR1HRH3NPY5RAVPR1ACFTR | |
| SCHEMBL8777675 | 0.90 | SIGMAR1 (0.61) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL612153 | 0.83 | SIGMAR1 (0.55) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL18854250 | 0.83 | SIGMAR1 (0.55) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL15710462 | 0.83 | SIGMAR1 (0.55) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL15076889 | 0.81 | SIGMAR1 (0.54) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL11839999 | 0.81 | SIGMAR1 (0.54) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL171980 | 0.81 | SIGMAR1 (0.54) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL29674557 | 0.81 | SIGMAR1 (0.54) | SIGMAR1NPY5RAVPR1ACFTRGOPC | |
| SCHEMBL3401467 | 0.81 | SIGMAR1 (0.54) | SIGMAR1NPY5RAVPR1ACFTRGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050104233-A1 | Method of substituent introduction through halogen-metal exchange reaction | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1510510-A1 | METHOD OF SUBSTITUENT INTRODUCTION THROUGH HALOGEN-METAL EXCHANGE REACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050104233-A1 | Method of substituent introduction through halogen-metal exchange reaction | SLC39A11, SLC30A6, SLC39A3 | SIGMAR1 2994/4885HRH3 639/4885NPY5R 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.